VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
EOCN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
EOCNEocene Ltd.
$2.46$3M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
EOCN logo

Eocene Ltd.

EOCN
NASDAQ · Metabolic & Cardiovascular Biotech
$2.46
At close - Nov 17, 4:00 PM EST - USD
Market Cap$3M
P/E-0.2x
52W High$10.08
Volume10.16K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Pre-Revenue Biotech Burning Cash Against Shrinking Equity Base

Eocene Ltd. is a pre-revenue metabolic and cardiovascular biotech with no recorded revenue or cost of goods sold across the ten quarters from 2024Q1 through 2026Q2, leaving its value dependent entirely on pipeline progress rather than current earnings.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

EOCN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 46 · Lag

Laggard (Underperforming 54% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Dec 2

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
EOCN-62.61%
S&P 500 (^GSPC)+7.21%
1-Year Return
EOCN+134.29%
S&P 500 (^GSPC)+10.03%
3-Year Return
EOCN-49.69%
S&P 500 (^GSPC)+58.27%
5-Year Return
EOCN-99.51%
S&P 500 (^GSPC)+55.78%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$10M-37.1% YoY
Free cash flow FY25
-$6M-7.4% YoY
Operating margin FY25
-
ROIC (FY25)-54.4%
Avg ROIC 5Y-57.6%
ROE (TTM)-73.7%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (63%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Sep 2, 2026
-$2.86+8.3%
vs -$3.12
—
vs —
Q3 2026
Jul 8, 2026
-$2.32+23.7%
vs -$3.04
—
vs —
Q2 2026
May 20, 2026
-$0.92-142.1%
vs -$0.38
—
vs —
Q2 2026
Mar 31, 2026
-$0.92-80.4%
vs -$0.51
—
vs $1M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

3 Stories
PRNewsWire·Nov 10, 2026
Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device

GIVATAYIM, Israel, Nov. 10, 2026 /PRNewswire/ -- Eocene Ltd. (NASDAQ: EOCN) ("Eocene" or the "Company") today announced that its wholly owned subsidiary, Colospan Ltd. ("Colospan"), has entered into its first European commercial distribution agreement for its CG-100 device with Hospital Line SA ("Hospital Line"). Under the agreement, Hospital Line has been granted exclusive rights to market, sell and distribute CG-100 in Greece and Cyprus. Colospan intends for the agreement to serve as a foundation for the potential further commercial expansion of CG-100 into additional European markets. The planned commercial launch of CG-100 in Greece and Cyprus is expected to proceed in parallel with Colospan's ongoing U.S. pivotal study of CG-100.

PRNewsWire·Sep 9, 2026
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (Yorkville) will be terminated effective immediately The Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and will continue to be listed and traded on the Nasdaq Capital Market under the new ticker symbol RAMAT-GAN, Israel, Sept.

Defense World·Aug 20, 2026
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $4.53 and traded as high as $5.4501. Galmed Pharmaceuticals shares last traded at $4.77, with a volume of 225,638 shares changing hands. Analyst Upgrades and

Filtered for Eocene Ltd.More Headlines
04

Compare before deciding

Benchmark EOCN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Eocene Ltd. (EOCN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
EOCN logoEOCNEocene Ltd.Current
$2.46$2.63M-0.21——-73.68%—
MDGL logoMDGLMadrigal Pharmaceuticals, Inc.
$421.99$9.73B-82.28432.05%-10.89%-27.07%—
AKBA logoAKBAAkebia Therapeutics, Inc.
$0.40$107.41M-2.4947.46%-22.6%-169.15%—
HALO logoHALOHalozyme Therapeutics, Inc.
$95.97$11.38B24.2437.55%26.93%544.26%—
VKTX logoVKTXViking Therapeutics, Inc.
$26.88$3.14B-5.06——-117.35%—
ALNY logoALNYAlnylam Pharmaceuticals, Inc.
$156.50$20.89B7.9365.19%54.34%159.72%—

Compare EOCN vs Peers

Eocene Ltd. (EOCN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MDGL

Most directly comparable listed peer for EOCN.

Scale Benchmark

vs LLY

Larger-name benchmark to compare EOCN against a more recognizable public peer.

Peer Set

Compare Top 5

vs MDGL, AKBA, HALO, VKTX

Get notified when EOCN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

EOCN Frequently Asked Questions

Eocene Ltd. (EOCN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is EOCN profitable?

No. Eocene Ltd. (EOCN) reported a net loss of $11.3M over the trailing twelve months.

Dividend & Returns
What is EOCN's return on equity?

Eocene Ltd. (EOCN) had a return on equity (ROE) of -73.7% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Eocene Ltd.'s free cash flow?

Eocene Ltd. (EOCN) had negative free cash flow of $8.5M over the trailing twelve months.

What if you invested $1,000 in EOCN back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →